ES2113878T3 - Proteina c hibrida. - Google Patents

Proteina c hibrida.

Info

Publication number
ES2113878T3
ES2113878T3 ES91901991T ES91901991T ES2113878T3 ES 2113878 T3 ES2113878 T3 ES 2113878T3 ES 91901991 T ES91901991 T ES 91901991T ES 91901991 T ES91901991 T ES 91901991T ES 2113878 T3 ES2113878 T3 ES 2113878T3
Authority
ES
Spain
Prior art keywords
human
protein
modified
molecules
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91901991T
Other languages
English (en)
Inventor
Donald C Foster
Richard D Holly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ES2113878T3 publication Critical patent/ES2113878T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROTEINA C HIBRIDA LAS MOLECULAS DE LA PROTEINA C HUMANA SE MODIFICAN PARA PROPORCIONAR UNA MAYOR RESISTENCIA A LA INACTIVACION MEDIANTE FACTORES DE PLASMA HUMANOS AL TIEMPO QUE SE MANTIENE SUSTANCIALMENTE LA ACTIVIDAD BIOLOGICA DE LA PROTEINA C HUMANA. LAS MODIFICACIONES SE HACEN NORMALMENTE EN LA CADENA PESADA DE LA PROTEINA C, CUYA CADENA PUEDE SER SUSTITUIDA POR UNA CADENA PESADA DE PROTEINA C DE ORIGEN NO HUMANO, COMO POR EJEMPLO BOVINO, LO QUE DA LUGAR A UNA MOLECULA DE LA PROTEINA C QUIMERICA. LA CADENA PESADA DE LA PROTEINA C HUMANA SE PUEDE MODIFICAR TAMBIEN PARA QUE SEA TIPO HUMANA PUESTO QUE AL MENOS UN AMINOACIDO DE UNA SECUENCIA NO HUMANA SE PUEDE SUSTITUIR POR EL RESIDUO O RESIDUOS CORRESPONDIENTES DE LA SECUENCIA HUMANA, PERMITIENDO ASI QUE LA MOLECULA SIGA TENIENDO CARACTERISTICAS HUMANAS AL TIEMPO QUE SIGUE PRESENTANDO UNA MAYOR RESISTENCIA A LA INACTIVACION. TAMBIEN SE INCLUYEN LOS METODOS PARA PRODUCIR LAS MOLECULAS DE PROTEINA C MODIFICADAS Y LAS COMPOSICIONES FARMACEUTICAS DE LAS MISMAS. LAS MOLECULAS MODIFICADAS, QUE TIENEN UNA VIDA MEDIA MAYOR EN EL PLASMA HUMANO, SON PARTICULARMENTE UTILES PARA EL TRATAMIENTO DE DESORDENES RELACIONADOS CON LA COAGULACION, TALES COMO UNA DEFICIENCIA DE PROTEINA C O TROMBOSIS O PARA FOMENTAR LA FIBRILINOSIS DE UN PACIENTE.
ES91901991T 1989-12-29 1990-12-28 Proteina c hibrida. Expired - Lifetime ES2113878T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45885689A 1989-12-29 1989-12-29
US51537890A 1990-04-27 1990-04-27
PCT/US1990/007693 WO1991009960A1 (en) 1989-12-29 1990-12-28 Hybrid protein c

Publications (1)

Publication Number Publication Date
ES2113878T3 true ES2113878T3 (es) 1998-05-16

Family

ID=27039137

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91901991T Expired - Lifetime ES2113878T3 (es) 1989-12-29 1990-12-28 Proteina c hibrida.

Country Status (11)

Country Link
US (1) US5766921A (es)
EP (1) EP0506821B1 (es)
JP (1) JP3270462B2 (es)
AT (1) ATE163048T1 (es)
AU (1) AU7168591A (es)
CA (1) CA2071630C (es)
DE (1) DE69032029T2 (es)
DK (1) DK0506821T3 (es)
ES (1) ES2113878T3 (es)
GR (1) GR3026414T3 (es)
WO (1) WO1991009960A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
SV1999000067A (es) * 1998-06-01 2000-07-06 Lilly Co Eli Proteina humana c polipeptida ref. x-12279
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
AU4188500A (en) * 1999-04-30 2000-11-17 Eli Lilly And Company Protein c derivatives
JP2003514545A (ja) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
ES2234807T3 (es) 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
JP4071105B2 (ja) * 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインｃまたは活性化プロテインｃ様分子
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
BRPI0514396A2 (pt) * 2004-08-17 2009-05-12 Csl Behring Gmbh polipeptìdeos dependentes de vitamina k modificada
EP2242875A4 (en) * 2008-01-15 2012-04-04 Univ British Columbia PROTEIN C RS2069915 AS A SURVIVOR RESPONSE PREDICTOR AND ADMINISTRATION OF PROTEIN C OR AN ACTIVE PROTEIN C COMPOUND
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
DE3688900T3 (de) * 1985-06-27 1998-06-10 Univ Washington Expression von Protein C.
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
EP0245949B1 (en) * 1986-04-09 1997-10-29 Eli Lilly And Company A method of using eukaryotic expression vectors comprising the bk virus enhancer
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
JPH03501921A (ja) * 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
JP2643968B2 (ja) * 1988-02-03 1997-08-25 サントリー株式会社 Ｋｅｘ２エンドプロテアーゼ及びその製造方法
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
FI85342C (fi) * 1989-02-03 1992-04-10 Tampella Oy Ab Foerfarande och anordning foer befuktning av partiklar i gasstroemningen.
CA2047702C (en) * 1989-03-06 2000-10-24 Joseph F. Sambrook Serpin resistant chymotrypsin superfamily proteases particularly pai-1 resistant t-pa, complementary inhibitor mutants; compositions; genes; expression
JP3045307B2 (ja) * 1989-08-11 2000-05-29 ザイモジェネティクス，インコーポレイティド 活性化プロテインｃを生成するための細胞培養法

Also Published As

Publication number Publication date
EP0506821A1 (en) 1992-10-07
JP3270462B2 (ja) 2002-04-02
CA2071630C (en) 2000-02-22
DE69032029D1 (de) 1998-03-12
WO1991009960A1 (en) 1991-07-11
US5766921A (en) 1998-06-16
CA2071630A1 (en) 1991-06-30
EP0506821A4 (en) 1992-11-04
EP0506821B1 (en) 1998-02-04
GR3026414T3 (en) 1998-06-30
AU7168591A (en) 1991-07-24
DE69032029T2 (de) 1998-08-20
DK0506821T3 (da) 1998-03-30
ATE163048T1 (de) 1998-02-15
JPH06502986A (ja) 1994-04-07

Similar Documents

Publication Publication Date Title
ES2113878T3 (es) Proteina c hibrida.
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
DE3484616D1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
FI905956A0 (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
GR3025596T3 (en) Compositions and methods for identifying biologically active molecules.
ATE312119T1 (de) Glucagonähnliche peptide, zusammensetzungen und verfahren
DE69430253D1 (de) Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen
DE69133509D1 (de) Verfahren zur herstellung von beta-lactamen
DE60102147D1 (de) Anti-gefrier proteine, deren herstellung und verwendung
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
ATE211390T1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
AR004093A1 (es) El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas.
DE69113049D1 (de) Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
ATE452139T1 (de) Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind
BG60657B2 (en) Human recombinant interleukin-2 muteins
UA23145A (uk) Спосіб визhачеhhя активhості бромелаїhу
DE60326157D1 (de) Verfahren zur identifizierung von modulatoren der glucoseaufnahme
ES2004438A6 (es) Un metodo para producir una proteina trombolitica
MX9504057A (es) Proteina que tiene actividad tpo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506821

Country of ref document: ES